Suma Krishnan, serving as President of Research & Development at Krystal Biotech, Inc. (NASDAQ:KRYS), has executed a significant divestment of company equity, selling 25,000 shares of common stock on June 4, 2026. The total value of the transaction reached approximately $7,702,825, with shares changing hands at prices fluctuating between $300.75 and $311.65. This sale was facilitated through a Rule 10b5-1 trading plan, a structured arrangement designed to allow executives to manage equity positions without facing allegations of insider trading. Krishnan initially adopted this plan on September 4, 2025, and it officially commenced operations on December 4, 2025. The plan is scheduled to conclude on December 4, 2026, or earlier if all shares designated under the agreement are fully liquidated.
The timing of this executive sale is notable given the current market position of Krystal Biotech. The company's stock is trading near its 52-week high of $319.48, a level that reflects a remarkable 127% return over the past year. Despite the strong price appreciation, InvestingPro analysis suggests that the stock remains slightly undervalued relative to its Fair Value. This valuation perspective is supported by the company's financial health, which includes an impressive gross profit margin of 94% and a balance sheet that holds more cash than debt. These metrics indicate a robust operational foundation, even as the stock price has surged.
Following the recent transaction, Krishnan's direct ownership in Krystal Biotech stands at 1,378,155 shares. Her beneficial ownership extends beyond direct holdings, encompassing 90,000 shares held through the Krishnan Spousal Trust, where she serves as a co-trustee, and an additional 50,000 shares via the Krishnan Family Trust. In the latter arrangement, she and her spouse are joint beneficial owners with joint voting and investment control. The filing also notes that Krishnan may be deemed to beneficially own shares held directly by her spouse, Krish S. Krishnan, though these shares and their transactions are reported separately on a Form 4 filed by her spouse, and Krishnan disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein.
Corporate developments surrounding Krystal Biotech include significant regulatory and financial milestones. The United Kingdom Medicines and Healthcare products Regulatory Agency has granted marketing authorization to the company's gene therapy, VYJUVEK, for treating wounds in patients with dystrophic epidermolysis bullosa. This approval marks VYJUVEK as the first genetic medicine approved in the UK for this condition, representing a critical expansion in the company's global market reach. Financially, Krystal Biotech reported first-quarter 2026 earnings that exceeded expectations, with earnings per share of $1.83 against a forecast of $1.48, a 23.65% beat. Revenue for the quarter reached $116.4 million, surpassing consensus estimates of $113 million and BofA Securities' estimate of $110 million. This revenue comprised $87 million from the U.S. and $29 million from international markets. Despite these positive results, BofA Securities adjusted its price target for Krystal Biotech downward to $323 from $325, while maintaining a Buy rating on the stock.